Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland | ||
By: GlobeNewswire - 19 Feb 2024 | Back to overview list |
|
ORION CORPORATION PRESS RELEASE 19 FEBRUARY 2024 at 13:15 EET Orion Corporation is evaluating the possible outsourcing of its pharmaceutical production in Kuopio, part of its Global Operations function, to an entity outside Finland. The basis for the possible outsourcing would be the lack of competitiveness of the Kuopio plant and the high investment needs of the plant. The evaluation is due to the low competitiveness of the plant, low capacity utilisation, increasing quality requirements in the pharmaceutical industry, and high investment needs. Volumes of the plant are low and due to the lack of competitiveness, outlook for growth is very limited. Therefore, the additional investment needed would not be justified. The products currently manufactured in Kuopio would continue to be part of Orion’s product portfolio also in the future. The estimated time scope is that the plant would continue to operate until at least the summer of 2026. Orion’s manufacturing plant in Kuopio specialises in liquids and self-care products. Among the most widely known of the products manufactured in Kuopio are nasal sprays, cough medicines, and ear drops. Orion’s Global Operations and Quality Management have about 1,900 employees in total. Global Operations consists of production at Orion's own plants in Espoo, Turku, Kuopio and Salo; an external supplier network; procurement; and Fermion Oy, which manufactures active pharmaceutical ingredients in Hanko and Oulu. Terhi Ormio, VP, Communications Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. Publisher: |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |